Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · Real-Time Price · USD
2.845
-0.140 (-4.69%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Processa Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-13.56-11.85-11.12-27.42-11.43
Upgrade
Depreciation & Amortization
0000.790.79
Upgrade
Other Amortization
---0.12-
Upgrade
Asset Writedown & Restructuring Costs
---7.270.3
Upgrade
Stock-Based Compensation
0.860.631.068.833.41
Upgrade
Other Operating Activities
-0.220.091.390.27-0.61
Upgrade
Change in Accounts Receivable
---0.070.01
Upgrade
Change in Accounts Payable
0.180.57-0.020.11-0.1
Upgrade
Change in Other Net Operating Assets
1.37-0.680.620.36-1.08
Upgrade
Operating Cash Flow
-11.39-11.25-8.06-9.61-8.72
Upgrade
Capital Expenditures
--0-0--
Upgrade
Other Investing Activities
-0.85----
Upgrade
Investing Cash Flow
-0.85-0-0--
Upgrade
Long-Term Debt Repaid
-0.01-0.01---
Upgrade
Net Debt Issued (Repaid)
-0.01-0.01---
Upgrade
Issuance of Common Stock
16.67.766.32-10.05
Upgrade
Repurchase of Common Stock
-0.01-0.02-0.05-0.39-0.06
Upgrade
Other Financing Activities
-----0.19
Upgrade
Financing Cash Flow
16.587.736.27-0.399.8
Upgrade
Net Cash Flow
4.35-3.51-1.8-9.991.08
Upgrade
Free Cash Flow
-11.39-11.25-8.07-9.61-8.72
Upgrade
Free Cash Flow Per Share
-8.70-91.87-153.75-298.12-284.52
Upgrade
Cash Interest Paid
0.010---
Upgrade
Levered Free Cash Flow
-6.55-5.85-4.11-2.96-4.19
Upgrade
Unlevered Free Cash Flow
-6.55-5.85-4.11-3.08-4.19
Upgrade
Change in Working Capital
1.54-0.110.610.54-1.18
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.